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NEUROLOGIC COMPLICATIONS OF PHENOTHIAZINE THERAPY 
JOHN R. DUBOIS, JR., M.D.* 
In 1953, chlorpromazine (Thorazine) was introduced in the United States as the 
first phenothiazine drug to be used as a tranquilizer. This was the beginning of a major 
break-through in the treatment of mental illness, and since that time literally scores 
of other phenothiazine drugs have been introduced into the medical field, not only for 
the management of anxiety and agitation, but also in the treatment of other symptoms 
e.g. nausea, vomiting and skin conditions associated with pruritus. The influence that 
phenothiazine drugs and other tranquilizing agents have had on the management of 
mental illness in the United States is evidenced by the fact that in 1956 the inpatient 
population in State and Federal Mental Institutions decreased for the first time in 
history. At the end of 1955, the nation's public mental hospitals had 558,922 resident 
patients. By the end of 1961, the figure had decUned to 527,945. Although other factors 
contributed to this decline, the phenothiazines are widely acclaimed as the biggest single 
factor. In that same period prescription sales (not including sales to hospitals) for all 
tranquilizers doubled from 100 to 200 million dollars. The phenothiazines made up 
about 50 percent of those sales." 
There are many side effects which potentially may occur in the use of 
phenothiazine therapy. Some of these are well known e.g. jaundice, granulocytopenia, 
cutaneous eruptions, thrombocytopenia, gastroenteritis (which is an early warning of 
liver involvement,^ and hypotension. Although hypotension may occur in any patient, 
those most likely to react this way will be the alcoholics, or those patients having 
arteriosclerosis or heart disease'. Also parenteral chlorpromazine seems to be indicated 
more than the other phenothiazines. The less well known side effects of this group of 
drugs may cause considerable bewilderment to the physician who sees them for the first 
time e.g. galactorrhea, photosensitivity, muscle or joint pains, edema of the extremities, 
hyperpyrexia, depersonalization, toxic psychosis,^  hairy tongue and neurologic signs. 
The hairy tongue has been reported to occur on large doses of chlorpromazine and 
disappeared within 2 weeks after discontinuation of therapy". The neurological signs 
are the most bewildering and may be grouped into five clinical pictures: dystonia, 
grand mal convulsions. Parkinsonism, akathisia, and catatonia. These will be discussed 
in more detail below. 
•Division of Psychiatry. 
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When phenothiazine drugs were first administered to children it was felt that the 
pediatric dose would merely be in proportion to that for adults. However, evidence 
suggests that much greater sensitivity prevails in childhood which is in contradistinction 
to other drugs where children have a relative tolerance much greater than that for adults 
e.g. atropine or digitalis. In infants, the extreme sensitivity of phenothiazine drugs 
appears to be due to the immaturity of the microsome enzyme system in the liver which 
functions at only a fraction of its adult efficiency. Consequently, the drug cannot be 
detoxified rapidly for the kidney to excrete." This same enzyme system is responsible 
for infants having very little tolerance to many other drugs e.g. ephedrine, aspirin, 
codeine, chloramphenicol and the sulfa drugs. The phenothiazine dosage in children 
cannot be extrapolated from that which is appropriate for adults or experimental animals. 
Although chlorpromazine is secreted in the milk of lactating women, it is barely 
detectable and well below even the pediatric dose for infants." The pediatric dose of 
chlorpromazine is 0.1 mgm. per pound every four to six hours. 
Much has been written about the safe use of chlorpromazine during labor to 
enhance the effect of analgesics and sedatives thus making a smaller dose required and 
minimizing the respiratory depression effect of these drugs on the newborn infant. 
In the material reviewed Chlorpromazine was given in doses of 25 to 150 mgm. during 
the 24 hours preceding delivery. However, in mothers receiving 500 mg. or more of 
chlorpromazine per day in the latter part of pregnancy, there was a significant respiratory 
depression found in the newborn infants." 
The above mentioned neurological signs occur in both children and adults. These 
reactions are usually alarming and surprising to the doctor who sees them for the first 
time. A number of factors contribute to the uncertainties of the situation:'" 1. When 
these drugs were first introduced a wide and generous dosage range was implied. 2. 
Many children and some adults appear to be extremely sensitive to these agents and 
some developed complications well within the propitious dosage range. 3. There may be 
a several hour or even day latency period between the administration of the drug and 
the appearance of the side effects. 4. Patients with acute central nervous system 
infections or with severe dehydration appear to be extremely sensitive to phenothiazine 
drugs. 5. In some cases even after the drug has been discontinued and anti-Parkinson 
drug therapy has been instituted, there may be a continuation of side effects for a 
long time. 6. The neurological signs are not limited to any particular phenothiazine and 
can occur with any phenothiazine preparation. 
* * * * ^ 
The grouping of the neurological signs into the categories of dystonia, convulsions. 
Parkinsonism, akathisia, and catatonia is made for clinical reasons because usually only 
one of the group of these signs will occur in a given patient. However, any or all 
of the neurological signs may be found in a patient receiving any member of the 
phenothiazine group. The etiology, however, is felt to be similar, that is, the drugs cause 
either a stimulation of the basal ganglia and reticular formation or a diminishment of 
the inhibitory impulses to these areas which come from the cortex. There appears to 
be a positive correlation between the incidence of dystonia, akathisia, and Parkinsonism 
and the milligram potency of the phenothiazine. Thus the piperazine subgroup repre-
.sented by Permitil (fluphenazine), Stelazine (trifluoperazine), Trilafon (perphenazine). 
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Dartal (thiopropazate), and Compazine (prochlorperazine) have a much higher inci-
dence of these neurologic signs than do the aliphatic subgroup represented by Vesprin 
(triflupromazine), Thorazine (chlorpromazine), Tentone (methoxypromazine), and 
Sparine (promazine). However, the latter group has a higher incidence of convulsions, 
sedation, autonomic side effects, dermatitis, jaundice, and agranulocytosis. 
Some of the dystonic signs are referred to as "pseudotetanus".'" This includes 
trismus, difficulty in swallowing, and spasmodic movements of the face, palate, neck 
and extremities. Occasionally, there is only involuntary spasms of the neck muscles, 
often unilateral. This may become violent, severe and involve all of the neck muscles. 
Other signs are; Spasm of the masseters, involuntary movement of the pharyngeal 
musculature, salivation which may be excessive, loud involuntary shrieks which may 
resemble the barking of a dog, and extensor spasm of the upper or all four extremities. 
At times the above signs are so sudden and dramatic in onset that they can be 
mistaken for an epileptic seizure. One case was reported in which dystonic signs 
occurred 20 hours after a single injection of fluphenazine (Prolixin or Permitil).' 
Cyanosis due to respiratory distress, protrusion of the tongue, inability to focus the 
eyes, fixation of the eyes to one side or upwards (oculogyric crisis), or opisthotonos 
may also occur as additional dystonic signs." The onset of dystonic signs may vary 
from two hours to as long as six days after the institution of phenothiazine therapy. 
In fact, 90 percent of the cases of dystonia resulting from phenothiazines had their 
onset within the first 4'/2 days after the drug was started.'' Signs have persisted up 
to 48 hours after the drug was discontinued.' The length of these attacks may vary 
from a few seconds to one hour. 
As mentioned above a grand mal convulsion may be the only manifestation of a 
phenothiazine idiosyncrasy. With the dystonic signs there is no loss of consciousness, 
but when a typical grand mal convulsion occurs there will also be unconsciousness. 
At these times the EEG will show a typical tracing of a seizure pattern. However, 
there may be some dystonic signs resembling a convulsion with consciousness retained. 
The EEG then does not show the high voltage spiking of a seizure pattern. The usual 
EEG pattern in a person taking therapeutic doses of phenothiazine is variable, but 
usually in the normal (Alpha) range of frequency. However, there may be slower 
frequencies (Theta) found in the frontal and temporal areas that are similar to tracings 
found in focal lesions. When toxic doses are given the EEG pattern is one of very 
low frequency (Delta). The EEG obtained while the patient is having dystonic signs, 
however, does not show low frequency. This suggests that the dystonic reaction is more 
of a drug idiosyncrasy than a drug intoxication. 
One might ask if abrupt withdrawal of high phenothiazine doses causes convulsions. 
In my experience I have never seen this. Two articles report other withdrawal mani-
festations but no seizures. In one study" 17 out of 28 patients suffered a moderate 
withdrawal reaction similar to that noted after opiate withdrawal (tenseness, 
myalgia, cold sweats, insomnia, nausea, and vomiting) beginning two to five days 
after withdrawal. However, the patients were given a placebo substitute which was 
interpreted by both patients and staff as a very powerful and dangerous drug with 
serious side effects. In another study'" in which no placebo was substituted, over 
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500 patients were abruptly withdrawn. The most severe symptoms reported were 
malaise, insomnia, and diaphoresis. 
The Parkinson-like syndrome is the most commonly observed neurological side 
effect of phenothiazine therapy. In descending frequency the initial Parkinsonian 
sign is: Cogwheel rigidity of the limbs, loss of associated movements, facial rigidity, 
skin changes (an oily or waxy texture), gait disturbances, drooling, and poverty 
of movement. The cogwheel rigidity of the limbs, however, usually is mild, but the 
loss of associated movements may become very severe if therapy is continued. It is 
felt that the loss of associated movement is a rather sensitive indicator of the onset 
of Parkinsonian signs as a result of the phenothiazine therapy and thus is a good subtle 
clinical sign." Ninety percent of patients who develop Parkinsonism on these drugs 
will manifest it within the first 72 days of therapy.'" The duration of signs beyond 
cessation of therapy would, in a great majority of cases, end within a month. However, 
some of the signs persist as long as three months after therapy is discontinued. One 
interesting report' claims that of 83 patients who developed Parkinsonian signs on 
phenothiazine therapy and were concurrently treated with an anti-Parkinson drug, 
only 17 of these patients had a recurrence of Parkinson signs when the anti-Parkinson 
drug was discontinued and while the high dose of a phenothiazine was maintained. 
This would suggest that the Parkinson picture was a transient side effect of phenothiazine 
therapy. 
Another neurological sign which is usually found singularly is akathisia. It is 
a paradoxical effect of phenothiazine therapy i.e. it seems to make the patient more 
anxious than he was before therapy began. It is felt to be an unusual manifestation 
of the Parkinsonian syndrome.'^ Many subjects will complain paradoxically that they 
cannot sit still or do so only with an effort. They must get up, or move about, 
or shift the position of their limbs, inactivity having become unbearable. I f akathisia 
is mild, patients complain of a feeling of inner unrest of pulling or drawing sensation 
in the extremities, but chiefly in the legs. Just as in Parkinsonism, ninety percent 
of the patients who developed akathisia did so within the first 73 days of therapy." 
Once akathisia has fully developed, patients pace back and forth and they can neither 
sit down to read nor play nor sleep. In severe cases, patients appear continuously 
agitated. In one study' when akathisia was found to occur in a patient another potent 
phenothiazine drug was substituted in which akathisia did not develop. 
The f i f th neurological side effect that is seen clinically is catatonia. This catatonic-
like state may indeed mimic schizophrenia, that is, they may manifest waxy flexibility 
(catalepsy), decreased motor activity, moderate negativism, tremor, and stereotypy, 
which means the persistent repetition of senseless acts or words. Although one cannot 
exclude the possibility that patients with this reaction are basically schizophrenic, the 
fact that the episodes develop while under phenothiazine medication and disappear 
following withdrawal of the drug indicated definite participation of the phenothiazine 
in the symptoms." 
The treatment of any of the above neurologic side effects consists of discontinuing 
the drug immediately if the signs are moderate or severe. If only mild signs occur, 
an explanation to the patient and the addition of an anti-Parkinson drug usually is 
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sufficient. The use of caffeine sodium benzoate, 500 mgm. intramuscularly or intra-
venously, or the use of Benedryl, 10 to 50 mgm. I M or IV, are reported to give dramatic 
relief from the dystonic reactions. The significance of recognizing these complications of 
phenothiazine therapy is twofold. One, the psychological effects can be very disrupting 
to the patient if he is not reassured as to the cause of his distress. The second 
significance is that the signs may mimic hysteria, epilepsy, bulbar polio, encephalitis 
(particularly the Von Economo type), catatonic schizophrenia, or tetanus. If the true 
etiology is not recognized, therapy can be a delinite hazard to the patient. 
In the literature that was reviewed it was noted that there was no positive 
correlation between neurologic signs and liver dysfunction. Also there was only a 
weak and equivocal association of neurologic side effects with psychiatric improvement. 
This then would give less support to the opinions held by some psychiatrists that there 
is greater psychiatric improvement in those patients developing neurologic side effects 
while on phenothiazine therapy. 
In conclusion, it is hoped that the physician will recognize the relationship 
between the use of phenothiazine drugs and the unusual and even bizarre side effects 
that they may produce. By broadening our clinical horizons the doctor-patient rela-
tionship is improved and both will benefit from the added knowledge. 
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